Reach Us +18507546199

Journal of Regenerative Medicine ISSN: 2325-9620

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Platelet-Rich Plasma Therapies:In the Right Pathway to Find their Regulatory Niche

Platelet-Rich Plasma Therapies:In the Right Pathway to Find their Regulatory Niche

The Spanish Agency of Medicines and Medical Devices (AEMPS) has recently regulated the use of platelet-rich plasma (PRP), that is,patient’s own plasma enriched in platelets and therefore in proteins and growth factors, as a human use drug. It is the first time that one regulatory agency worldwide categorizes these types of therapeutic therapies. According to AEMPS, PRP approaches cannot be considered as an advanced-therapy medicinal product. PRPs are classified as non-industrial biological medicines, being subjected to a strict regulation in terms of production, validation, efficacy and safety.

Special Features

Full Text

View

Track Your Manuscript

Share This Page

Media Partners

Associations